Literature DB >> 33220258

PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback.

Luyan Shen1, Li Zhou2, Meihui Xia3, Nan Lin1, Jiaoyan Ma1, Delu Dong4, Liankun Sun5.   

Abstract

Mitochondria play an important role in effective cell energy production and cell survival under stress conditions, such as treatment with chemotherapeutic drugs. Mitochondrial biogenesis is increased in ovarian cancer tissues, which is accompanied by alteration of mitochondrial energy metabolism, structure, and dynamics. These factors are involved in tumorigenesis and apoptosis resistance, highlighting the role of mitochondria in resisting cisplatin toxicity. Cisplatin-resistant ovarian cancer cells are dependent on mitochondrial OXPHOS for energy supply, and intracellular PGC1α-mediated mitochondrial biogenesis levels are increased in this cell line, indicating the important role of mitochondrial oxidative phosphorylation in cisplatin resistance. As PGC1α is a key molecule for integrating and coordinating nuclear DNA and mitochondrial DNA transcriptional machinery, an investigation into the regulatory mechanism PGC1α in mitochondrial energy metabolism via transcription may provide new clues for solving chemotherapy resistance. In the present study, it was demonstrated that inhibiting the expression of PGC1α decreased nuclear and mitochondrial DNA transcription factor expression, leading to increased lactic acid production and decreased cellular oxygen consumption and mitochondrial oxidative phosphorylation. Furthermore, mitochondrial stress-induced ROS production, as a feedback signal from mitochondria to the cell nucleus, increased PGC1α expression in SKOV3/DDP cells, which was involved in mitochondrial oxidative phosphorylation regulation. Collectively, the present study provides evidence that PGC1α-mediated nuclear and mitochondrial transcription feedback regulates energy metabolism and is involved in ovarian cancer cells escaping apoptosis during cisplatin treatment.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Cisplatin resistance; Mitochondria; OXPHOS; Ovarian cancer; mtDNA transcription

Year:  2020        PMID: 33220258     DOI: 10.1016/j.yexcr.2020.112369

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer.

Authors:  Daniela Criscuolo; Rosario Avolio; Matteo Parri; Simona Romano; Paola Chiarugi; Danilo Swann Matassa; Franca Esposito
Journal:  Antioxidants (Basel)       Date:  2022-08-10

2.  A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expression.

Authors:  Nicole E James; Megan Gura; Morgan Woodman; Richard N Freiman; Jennifer R Ribeiro
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.738

Review 3.  Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies.

Authors:  Sepideh Mirzaei; Kiavash Hushmandi; Amirhossein Zabolian; Hossein Saleki; Seyed Mohammad Reza Torabi; Adnan Ranjbar; SeyedHesam SeyedSaleh; Seyed Omid Sharifzadeh; Haroon Khan; Milad Ashrafizadeh; Ali Zarrabi; Kwang-Seok Ahn
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

Review 4.  Sprifermin: Effects on Cartilage Homeostasis and Therapeutic Prospects in Cartilage-Related Diseases.

Authors:  Zongmian Song; Yusheng Li; Chunfeng Shang; Guowei Shang; Hongwei Kou; Jinfeng Li; Songfeng Chen; Hongjian Liu
Journal:  Front Cell Dev Biol       Date:  2021-12-14

Review 5.  Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.

Authors:  Ping Jin; Jingwen Jiang; Li Zhou; Zhao Huang; Edouard C Nice; Canhua Huang; Li Fu
Journal:  J Hematol Oncol       Date:  2022-07-18       Impact factor: 23.168

Review 6.  Targeting oxidative phosphorylation as an approach for the treatment of ovarian cancer.

Authors:  Yinjie Wu; Xuewei Zhang; Ziyi Wang; Wanzhen Zheng; Huimin Cao; Wenjing Shen
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

Review 7.  Mechanisms of chemotherapy resistance in ovarian cancer.

Authors:  Mylena Ortiz; Emma Wabel; Kerry Mitchell; Sachi Horibata
Journal:  Cancer Drug Resist       Date:  2022-04-03

Review 8.  Cisplatin for cancer therapy and overcoming chemoresistance.

Authors:  Ranmali Ranasinghe; Michael L Mathai; Anthony Zulli
Journal:  Heliyon       Date:  2022-09-14

9.  p62 Promotes the Mitochondrial Localization of p53 through Its UBA Domain and Participates in Regulating the Sensitivity of Ovarian Cancer Cells to Cisplatin.

Authors:  Qinghuan Kong; Xiaoyu Yan; Meiyu Cheng; Xin Jiang; Long Xu; Luyan Shen; Huimei Yu; Liankun Sun
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.